Form4insider filings, from the source

SEC Form 4 · accession 0001140361-18-019771

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jacob Van Naarden
Officer — Chief Business Officer
Period of report
Apr 24, 2018
Accepted (ET)
Apr 26, 2018 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockApr 24, 2018M1,541$3.648A1,541D
Common StockF2,F3Apr 24, 2018S241$129.581D1,300D
Common StockF2,F4Apr 24, 2018S300$130.6167D1,000D
Common StockF2,F5Apr 24, 2018S500$131.882D500D
Common StockF2,F6Apr 24, 2018S500$133.086D0D
Common StockApr 25, 2018M1,541$3.648A1,541D
Common StockF2,F7Apr 25, 2018S300$128.7167D1,241D
Common StockApr 25, 2018S100$129.45D1,141D
Common StockF2,F8Apr 25, 2018S600$130.935D541D
Common StockF2,F9Apr 25, 2018S541$132.0546D0D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (right to buy)F10$3.648Apr 24, 2018M1,541D—Jun 18, 2024Common Stock1,541102,756D
Employee Stock Option (right to buy)F10$3.648Apr 25, 2018M1,541D—Jun 18, 2024Common Stock1,541101,215D

Explanation of responses